VS
iShares Genomics Immunology and Healthcare Index ETF (XDNA) and CI Global Healthcare Leaders Index ETF (CHCL.B) offer distinct profiles for Canadian ETF investors. A direct comparison shows that XDNA focuses its top 3 sector exposures on Healthcare, while CHCL.B leans towards Healthcare, Consumer Non-Cyclicals, and Consumer Cyclicals. When evaluating costs, XDNA features a management fee (MER) of 0.39%, compared to 0.35% for CHCL.B. Performance-wise, XDNA has returned 53.58% year-to-date with +$6 M in net flows, whereas CHCL.B is at 9.74% with +$39 M. Use the comparison tool below to benchmark these funds across top 10 holdings, yield, sector weights and historical returns.
NAV Performance and Flows
Key Data
Compare
XDNA
CHCL.B
| AuM | $15.66 M | $135.75 M |
| Management Fees | 0.39% | 0.35% |
| Exp. ratio | 0.44% | 0.37% |
| Tracking Difference | -1.01% | - |
Historical performance and flows
As of September 4, 2026
| 1M | 3M | YTD | 1Y | 3Y | ||
|---|---|---|---|---|---|---|
| Perf. | XDNA | +18.91% | +32.72% | +53.58% | +77.75% | +84.03% |
CHCL.B | +3.20% | +10.57% | +9.74% | +21.66% | +32.15% | |
| Flows | XDNA | +$3 M | +$5 M | +$6 M | +$6 M | +$6 M |
CHCL.B | -$3 M | +$41 M | +$39 M | -$2 M | -$87 M |
XDNA vs CHCL.B exposure
Countries
XDNA
USA
60.39%
Germany
8.55%
France
7.33%
Other
23.74%
CHCL.B
USA
54.79%
Other
13.18%
Other
32.03%
Sectors
XDNA
Healthcare
99.82%
CHCL.B
Healthcare
84.05%
Other
13.18%
As of September 4, 2026
Top 10 Holdings
XDNA
Bayer AG
4.77%
Twist Bioscience Corp.
4.73%
Revolution Medicines, Inc.
4.61%
Moderna, Inc.
4.37%
Incyte Corp.
4.30%
Takeda Pharmaceutical Co., Ltd.
4.19%
Regeneron Pharmaceuticals, Inc.
4.16%
Genmab A/S
4.12%
Vertex Pharmaceuticals, Inc.
3.86%
Merck & Co., Inc.
3.85%
CHCL.B
AbbVie, Inc.
1.40%
Eli Lilly & Co.
1.29%
Johnson & Johnson
1.26%
Abbott Laboratories
1.22%
Pfizer Inc.
1.19%
Bristol Myers Squibb Co.
1.17%
CVS Health Corp.
1.17%
UnitedHealth Group, Inc.
1.15%
Merck & Co., Inc.
1.15%
Roche Holding AG
1.12%
Diversification
XDNA
Total weight of top 10 holdings out of 47 total
42.96%
CHCL.B
Total weight of top 10 holdings out of 150 total
12.13%
Characteristics
Compare
XDNA
CHCL.B
| Provider | iShares | CI |
| Management | Passively managed | Passively managed |
| Benchmark | NYSE FactSet Global Genomics and Immuno Biopharma NR Index - CAD | Solactive Developed Markets Healthcare 150 CAD Index (CA NTR) - CAD |
| Replication Method | Direct (Physical) | Direct (Physical) |
| Asset Class | Equity | Equity |
| Dividend Policy | Distributing | Distributing |
| Trailing 12m distribution yield | 0.21% | 1.05% |
| Meets ESG criteria | No | No |
| Inception Date | April 26, 2022 | August 17, 2021 |
Frequently asked questions about XDNA and CHCL.B
Which ETF has performed better year to date: XDNA or CHCL.B?
As of September 4, 2026, XDNA has returned 53.58% year to date, while CHCL.B has returned 9.74%. XDNA is ahead on YTD performance.
Which ETF is larger by assets under management: XDNA or CHCL.B?
As of September 4, 2026, XDNA manages $15.66 M in assets, while CHCL.B manages $135.75 M. CHCL.B is the larger fund by AUM.
How are XDNA and CHCL.B managed?
XDNA is passively managed by iShares. It tracks the NYSE FactSet Global Genomics and Immuno Biopharma NR Index - CAD benchmark. CHCL.B is passively managed by CI. It tracks the Solactive Developed Markets Healthcare 150 CAD Index (CA NTR) - CAD benchmark.
What sectors do XDNA and CHCL.B emphasize?
XDNA is most exposed to Healthcare. CHCL.B is most exposed to Healthcare, Consumer Non-Cyclicals, and Consumer Cyclicals.
Which ETF is attracting more investor flows: XDNA or CHCL.B?
Year to date, XDNA has seen +$6.43 M in net flows, compared with +$38.53 M for CHCL.B. CHCL.B has attracted more net investor money so far.
How do the fees of XDNA and CHCL.B compare?
XDNA has an expense ratio of 0.44%, while CHCL.B has an expense ratio of 0.37%.
What are the top holdings of XDNA and CHCL.B?
XDNA's largest holdings include Bayer AG, Twist Bioscience Corp., and Revolution Medicines, Inc.. CHCL.B's top holdings include Roche Holding AG, AbbVie, Inc., and Eli Lilly & Co..
Which ETF is more diversified: XDNA or CHCL.B?
XDNA holds 47 securities, while CHCL.B holds 149. On holdings count, CHCL.B is the more diversified portfolio.
Recent articles about XDNA and CHCL.B
The ETF Market Canada is brought to you by Cboe in partnership with Trackinsight SA who is providing all the data, analysis and editorial content on this site. Unless explicitly stated as such, any information that you receive is not real-time.
All content on the ETF Market Canada is for your general information use only, Cboe is not responsible for any use of content by you outside this scope. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by Cboe and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
All content on the ETF Market Canada is for your general information use only, Cboe is not responsible for any use of content by you outside this scope. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by Cboe and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.